B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)

Monica Balzarotti; Ercole Brusamolino; E. Angelucci; Angelo Michele Carella; U. Vitolo; Eleonora Russo; Angelagiovanna Congiu; Manuel Gotti; Stefania Massidda; B. Botto; Giorgia Annechini; Michele Spina; Alessandro Re; Vittorio Ruggero Zilioli; Francesco Merli; Flavia Salvi; Caterina Stelitano; Maurizio Bonfichi; Marcello Rodari; Roberta Murru; Massimo Magagnoli; Antonella Anastasia; Rita Mazza; Laura Giordano; Armando Santoro

doi:10.3109/10428194.2016.1140161

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)

Monica Balzarotti, Ercole Brusamolino, E. Angelucci, Angelo Michele Carella, U. Vitolo, Eleonora Russo, Angelagiovanna Congiu, Manuel Gotti, Stefania Massidda, B. Botto, Giorgia Annechini, Michele Spina, Alessandro Re, Vittorio Ruggero Zilioli, Francesco Merli, Flavia Salvi, Caterina Stelitano, Maurizio Bonfichi, Marcello Rodari, Roberta MurruMassimo Magagnoli, Antonella Anastasia, Rita Mazza, Laura Giordano, Armando Santoro

Research output: Contribution to journal › Article

Abstract

This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m²) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p

Original language	English
Pages (from-to)	2375-2381
Number of pages	7
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.3109/10428194.2016.1140161
Publication status	Accepted/In press - Feb 12 2016

Fingerprint

Keywords

Chemotherapeutic approaches
clinical results
lymphoma and Hodgkin lymphoma

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Cite this

Balzarotti, M., Brusamolino, E., Angelucci, E., Carella, A. M., Vitolo, U., Russo, E., Congiu, A., Gotti, M., Massidda, S., Botto, B., Annechini, G., Spina, M., Re, A., Zilioli, V. R., Merli, F., Salvi, F., Stelitano, C., Bonfichi, M., Rodari, M., ... Santoro, A. (Accepted/In press). B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). Leukemia and Lymphoma, 2375-2381. https://doi.org/10.3109/10428194.2016.1140161

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma : a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). / Balzarotti, Monica; Brusamolino, Ercole; Angelucci, E.; Carella, Angelo Michele; Vitolo, U.; Russo, Eleonora; Congiu, Angelagiovanna; Gotti, Manuel; Massidda, Stefania; Botto, B.; Annechini, Giorgia; Spina, Michele; Re, Alessandro; Zilioli, Vittorio Ruggero; Merli, Francesco; Salvi, Flavia; Stelitano, Caterina; Bonfichi, Maurizio ; Rodari, Marcello; Murru, Roberta; Magagnoli, Massimo; Anastasia, Antonella; Mazza, Rita ; Giordano, Laura ; Santoro, Armando.

In: Leukemia and Lymphoma, 12.02.2016, p. 2375-2381.

Research output: Contribution to journal › Article

Balzarotti, M, Brusamolino, E, Angelucci, E, Carella, AM, Vitolo, U, Russo, E, Congiu, A, Gotti, M, Massidda, S, Botto, B, Annechini, G, Spina, M, Re, A, Zilioli, VR, Merli, F, Salvi, F, Stelitano, C, Bonfichi, M , Rodari, M, Murru, R, Magagnoli, M, Anastasia, A, Mazza, R , Giordano, L & Santoro, A 2016, 'B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)', Leukemia and Lymphoma, pp. 2375-2381. https://doi.org/10.3109/10428194.2016.1140161

Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E et al. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). Leukemia and Lymphoma. 2016 Feb 12;2375-2381. https://doi.org/10.3109/10428194.2016.1140161

Balzarotti, Monica ; Brusamolino, Ercole ; Angelucci, E. ; Carella, Angelo Michele ; Vitolo, U. ; Russo, Eleonora ; Congiu, Angelagiovanna ; Gotti, Manuel ; Massidda, Stefania ; Botto, B. ; Annechini, Giorgia ; Spina, Michele ; Re, Alessandro ; Zilioli, Vittorio Ruggero ; Merli, Francesco ; Salvi, Flavia ; Stelitano, Caterina ; Bonfichi, Maurizio ; Rodari, Marcello ; Murru, Roberta ; Magagnoli, Massimo ; Anastasia, Antonella ; Mazza, Rita ; Giordano, Laura ; Santoro, Armando. / B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma : a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). In: Leukemia and Lymphoma. 2016 ; pp. 2375-2381.

@article{1273343eac644039be106998892892d3,

title = "B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)",

abstract = "This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p ",

keywords = "Chemotherapeutic approaches, clinical results, lymphoma and Hodgkin lymphoma",

author = "Monica Balzarotti and Ercole Brusamolino and E. Angelucci and Carella, {Angelo Michele} and U. Vitolo and Eleonora Russo and Angelagiovanna Congiu and Manuel Gotti and Stefania Massidda and B. Botto and Giorgia Annechini and Michele Spina and Alessandro Re and Zilioli, {Vittorio Ruggero} and Francesco Merli and Flavia Salvi and Caterina Stelitano and Maurizio Bonfichi and Marcello Rodari and Roberta Murru and Massimo Magagnoli and Antonella Anastasia and Rita Mazza and Laura Giordano and Armando Santoro",

year = "2016",

month = feb

day = "12",

doi = "10.3109/10428194.2016.1140161",

language = "English",

pages = "2375--2381",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma

T2 - a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)

AU - Balzarotti, Monica

AU - Brusamolino, Ercole

AU - Angelucci, E.

AU - Carella, Angelo Michele

AU - Vitolo, U.

AU - Russo, Eleonora

AU - Congiu, Angelagiovanna

AU - Gotti, Manuel

AU - Massidda, Stefania

AU - Botto, B.

AU - Annechini, Giorgia

AU - Spina, Michele

AU - Re, Alessandro

AU - Zilioli, Vittorio Ruggero

AU - Merli, Francesco

AU - Salvi, Flavia

AU - Stelitano, Caterina

AU - Bonfichi, Maurizio

AU - Rodari, Marcello

AU - Murru, Roberta

AU - Magagnoli, Massimo

AU - Anastasia, Antonella

AU - Mazza, Rita

AU - Giordano, Laura

AU - Santoro, Armando

PY - 2016/2/12

Y1 - 2016/2/12

N2 - This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p

AB - This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p

KW - Chemotherapeutic approaches

KW - clinical results

KW - lymphoma and Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84958544689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958544689&partnerID=8YFLogxK

U2 - 10.3109/10428194.2016.1140161

DO - 10.3109/10428194.2016.1140161

M3 - Article

SP - 2375

EP - 2381

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -

Access to Document

10.3109/10428194.2016.1140161